admin
President Trump’s most-favored-nation gambit just scored a major victory with Regeneron agreeing to join the White House drug-pricing deals, the last of 17 targeted manufacturers to sign on — a clear win for everyday Americans tired of getting gouged at the pharmacy counter. This is the kind of bold, unapologetic action Washington rarely takes unless forced by a leader who puts the country first, and it represents real political teeth against Big Pharma’s cozy status quo. The White House has moved from bluster to bargaining, and the American people are beginning to see the results.
This whole push traces back to President Trump’s executive action to deliver most-favored-nation pricing, an order that directed agencies to end the international freeloading that has let other countries pay less while Americans foot the bill. That executive order set the terms and put manufacturers on notice, creating leverage that this administration has used to extract concrete commitments. The policy is not theoretical — it was a directive meant to force accountability and to reorient pricing power away from middlemen and special interests.
What the deals actually do is straightforward and pro-American: lower Medicaid prices and make discounted cash prices available through the TrumpRx portal so patients can buy medicines directly without paying punishing markups. Drugmakers who signed on have pledged to match lower prices seen in peer nations for specific medicines, and some are offering negotiated discounts for cash-paying patients through the administration’s channels. These are the kinds of practical reforms that put Americans ahead of foreign governments and greedy intermediaries.
The quid pro quo has been fair and smart: companies that committed to U.S. price alignment also signed investment pledges for domestic manufacturing and received temporary tariff and enforcement relief, a deal that strengthens American industry and safeguards supply chains. That is conservative governing — leverage private investment for public benefit and secure American jobs while lowering costs for consumers. It’s a far cry from Washington’s usual habit of preaching free markets while letting monopolies and lobbyists run the table.
Of course, Washington Democrats and the usual suspects are trying to nitpick and demand paperwork rather than applaud savings, and some in the media are looking for caveats instead of celebrating wins for American families. Lawmakers on the left are calling for more transparency about exactly which drugs are covered and how states will implement the deals, which is to be expected from a party that prefers regulation theater to results. Still, the administration has shown it will use both carrots and sticks to achieve outcomes — and that’s the kind of results-driven leadership the country needs.
Even establishment medical voices have taken notice, with Dr. Deborah Birx appearing on Newsmax’s American Agenda to discuss how the president’s drug-pricing moves put the country in a stronger position to protect patients and taxpayers. Conservatives should welcome experts from across the aisle who recognize when policy actually helps Americans, and we should amplify those voices. Now is the moment for Republicans in Congress to codify these wins into law so every American can finally stop subsidizing the rest of the world’s drug purchases.
